



February 5,2023

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub:- Unaudited Financial Results for the quarter ended December 31, 2022 and Interim Dividend for the Financial Year 2022-23

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 12:04 p.m. and ended at 12:48 p.m.), the Unaudited Financial Results for the quarter ended December 31, 2022 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended December 31, 2022;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2022 furnished by Statutory Auditors of the Company

Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended an Interim Dividend for the Financial Year 2022-23 of Rs. 45 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before March 05, 2023.

As informed earlier in our letter dated January 16,2023, record date for the purpose of eligibility for payment of said Interim Dividend shall be February 13,2023.

Kindly take the same on record and oblige.

Thanking you,
Yours faithfully,

Zeal Shah
Company Secretary

Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Ground Floor and First Floor,
P&G Plaza, Cardinal Gracias Road, Chakala,
Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000
www.pghealthindia.com

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 31 DECEMBER 2022

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)	(6)
		Three months ended 31st December 2022 (Unaudited)	Preceding Three months ended 30th September 2022 (Unaudited)	Corresponding Three months ended 31st December 2021 (Unaudited)	Half Year ended 31st December 2022 (Unaudited)	Half Year ended 31st December 2021 (Unaudited)	Year ended 30th June 2022 (Audited)
1.	Revenue from Operations	30,997.0	29,755.0	27,790.0	60,752.0	55,070.0	111,441.0
2.	Other Income	454.0	342.0	470.0	796.0	774.0	1,319.0
3.	Total income (1+2)	31,451.0	30,097.0	28,260.0	61,548.0	55,844.0	112,760.0
4.	Expenses						
	a) Cost of materials consumed	10,108.0	8,022.0	9,315.0	18,130.0	17,699.0	32,372.0
	b) Purchases of stock-in-trade	773.0	516.0	524.0	1,289.0	1,175.0	2,083.0
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(2,739.0)	111.0	(735.0)	(2,628.0)	(1,780.0)	(475.0)
	d) Employee benefits expense	4,726.0	4,278.0	4,069.0	9,004.0	8,043.0	16,756.0
	e) Depreciation and amortisation expense	823.0	748.0	659.0	1,571.0	1,349.0	2,708.0
	f) Impairment	152.0	-	-	152.0	-	73.0
	g) Finance Costs	23.0	16.0	12.0	39.0	26.0	42.0
	h) Other expenses	7,091.0	7,746.0	8,433.0	14,837.0	15,942.0	33,864.0
	Total expenses (4)	20,957.0	21,437.0	22,277.0	42,394.0	42,454.0	87,423.0
5.	Profit before exceptional items and tax (3-4)	10,494.0	8,660.0	5,983.0	19,154.0	13,390.0	25,337.0
6.	Less: Exceptional items	-	-	-	-	-	-
7.	Profit before tax (5-6)	10,494.0	8,660.0	5,983.0	19,154.0	13,390.0	25,337.0
8.	Tax expenses						
	Current Tax	3,006.0	2,191.0	1,617.0	5,197.0	3,547.0	6,502.0
	Deferred Tax	(192.0)	103.0	10.0	(89.0)	(50.0)	4.0
	Tax for earlier years	-	-	(128.0)	-	(128.0)	(421.0)
9.	Net Profit for the period/ year (7-8)	7,680.0	6,366.0	4,484.0	14,046.0	10,021.0	19,252.0
10.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains/(losses) on defined benefit plans	(564.0)	23.0	(336.0)	(541.0)	(358.0)	94.0
	ii. Income tax effect	142.0	(6.0)	84.0	136.0	90.0	(24.0)
	Total Other Comprehensive Income, net of tax	(422.0)	17.0	(252.0)	(405.0)	(268.0)	70.0
11.	Total Comprehensive Income for the period/year (9+10)	7,258.0	6,383.0	4,232.0	13,641.0	9,753.0	19,322.0
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	-	-	59,989.0
14.	Earnings per equity share (of Rs 10/- each) *(not annualised)						
	(a) Basic and Diluted (in Rs.)	* 46.3	* 38.3	* 27	* 84.6	* 60.4	116



Mhas


PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

Notes:

1. The above results have been reviewed by Audit Committee and approved by the Board of Directors of the Company at meeting held on February 5, 2023 and have been subjected to a limited review by the Statutory Auditors of the Company.
2. Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
3. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.
4. The Board of Directors at its meeting held on February 5, 2023 has declared interim dividend for the current financial year 2022-23 of ₹45 per equity share (face value of ₹ 10 per equity share) aggregating to ₹ 7,470 lakhs (Gross) subject to deduction of tax at source as per applicable rate to the eligible shareholders.
5. Previous period figures have been regrouped/ reclassified wherever necessary.

For and on behalf of the Board of Directors of
Procter & Gamble Health Limited.


Milind Thatte
Managing Director

Place : Mumbai
Date : February 5, 2023
Please visit us at our website www.pghealthindia.com



PROCTER & GAMBLE HEALTH LIMITED

Notes:

1. Statement of Assets and Liabilities

(₹ in lakhs)

	As at December 31, 2022 [Unaudited]	As at June 30, 2022 [Audited]
ASSETS		
Non-current assets		
(a) Property, plant and equipment	10,987	10,635
(b) Capital work-in-progress	4,577	4,060
(c) Investment property	243	260
(d) Right-of-use assets	1,277	267
(e) Intangible assets	7	4
(f) Financial assets		
(i) Loans	570	599
(ii) Other financial assets	1,040	876
(g) Deferred tax assets (Net)	2,192	1,965
(h) Other non-current assets	777	956
(i) Non-current tax assets (Net)	8,394	8,386
Total non-current assets	30,064	28,008
Current assets		
(a) Inventories	16,737	11,521
(b) Financial assets		
(i) Trade receivables	10,213	8,344
(ii) Cash and cash equivalents	40,600	31,940
(iii) Bank balances other than (ii) above	529	513
(iv) Loans	153	157
(v) Other financial assets	675	746
(c) Other current assets	8,981	8,143
Total current assets	77,888	61,364
TOTAL ASSETS	107,952	89,372
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,660	1,660
(b) Other equity	71,786	59,989
Total Equity	73,446	61,649
Non-Current Liabilities		
(a) Financial liabilities		
(i) Lease liabilities	1,068	-
(b) Provisions	4,605	4,080
(c) Other non-current liabilities	63	60
Total non-current liabilities	5,736	4,140
Current liabilities		
(a) Financial liabilities		
Trade payables		
(i) total outstanding dues of micro enterprises and small enterprises	1,668	1,533
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises	20,674	16,068
Lease Liabilities	281	283
Other financial liabilities	2,560	3,025
Provisions	835	1,026
Current tax liabilities (net)	1,786	724
Other current liabilities	966	924
Total current liabilities	28,770	23,583
TOTAL EQUITY & LIABILITIES	107,952	89,372



[Handwritten Signature]

Procter & Gamble Health Limited

2. Cash Flow Statement

	Half Year Ended December 31, 2022 ₹ in lakhs	Year ended June 30, 2022 ₹ in lakhs
A. Cash Flows from Operating Activities		
Profit before tax	19,154	25 337
Adjustments for:		
Net unrealised foreign exchange loss	365	346
Allowance for doubtful receivables	144	159
Bad debts		7
Inventory written off	392	518
Provision/ write off of GST and other taxes	618	694
Depreciation of property, plant and equipment	1,571	2 708
Provision for Impairment	152	73
Income from letting of office premises	(103)	(213)
Provision for employee benefits	(579)	(138)
Provision for sales return/ expiries	(245)	(753)
Loss on sale of property, plant and equipment	30	54
Share-based payment to employees	65	341
Finance Cost	39	42
Interest income	(683)	(1 107)
Operating profit before working capital changes	20,920	28 068
Working capital adjustments:		
(Increase)/Decrease in inventories	(5,608)	(202)
(Increase)/Decrease in trade receivables	(2,215)	(2 515)
(Increase)/Decrease in financial and other Assets	(1,360)	(2 201)
(Decrease)/Increase in trade payables	4,579	(650)
Increase in other liabilities and provisions	1,670	838
Cash generated from operations	17,986	23 338
Income taxes paid (net)	(4,323)	(6 386)
Net cash generated from operating activities (A)	13,663	16 952
B. Cash Flows from Investing Activities		
Purchase and construction of property, plant and equipment	(3,622)	(3 792)
Proceeds from sale of asset	4	37
Income from letting of office premises	103	213
Interest received	706	988
Net cash (used in)/ generated from investing activities (B)	(2,809)	(2 554)
C. Cash flow from financing activities		
Dividend paid	(1,910)	(28 385)
Dividend tax paid	-	---
Payment of lease liability	(283)	(478)
Net cash flow used in financing activities (C)	(2,193)	(28 863)
Net (decrease)/ increase in cash and cash equivalents (A+B+C)	8,660	(14 464)
Cash and cash equivalents at the beginning of the year	31,940	46 405
Cash and cash equivalents at the end of the year	40,600	31 940
Components of Cash and Cash equivalents:		
Balance with Banks		
In Current accounts	8,100	3 800
In Term deposits (less than 3 months maturity)	32,500	28 140
	40,600	31 940



M. Khan



Procter & Gamble Health Announces Half Yearly Results

Sales up by 11% for quarter ended December 31, 2022

Mumbai, February 05, 2023: Procter & Gamble Health Limited today announced its financial results for the quarter ended December 31, 2022. The company has recorded a robust performance with sales of ₹ 304.7 crores for the quarter ended December 31, 2022, vs ₹ 273.3 crores a year ago, up by 11%. The Profit After Tax (PAT) was ₹ 76.8 crores vs ₹ 44.9 crores a year ago, supported by improved margin through portfolio premiumisation, healthy mix and optimization of expenses. Sales for the six-month period ending December 31, 2022, are ₹ 596.6 crores, vs ₹ 541.0 crores a year ago, up by 10%. Profit After Tax for same period is ₹ 140.5 crore vs ₹ 100.2 crore a year ago up by 40%.

Mr. Milind Thatte, Managing Director, P&G Health India, said, *“We delivered sales of ₹ 596.6 crores for half year, up by 10% over year ago, despite macroeconomic challenges, including rising inflation and high input costs. We have witnessed consistent growth over the second quarter and an overall promising first half of the year. Our encouraging financial results in the second quarter can be attributed to our core belief of bringing care closer to patients through innovative approaches. With continued focus on the health and wellness of patients and consumers, we launched Polybion A injection, a new and improved formulation, which can help doctors effectively manage the recovery of their patients, while giving a good boost to energy levels. On World Iron Deficiency Day, P&G Health in partnership with FOGSI (The Federation of Obstetric and Gynecological Societies of India) initiated the 'Na Na Anemia Bus Yatra', a 40-day Bus Yatra across 20 cities and 5 states to create awareness on Iron Deficiency Anemia. As a leader in Nerve Health and a partner to International Diabetes Federation, on World Diabetes Day 2022, P&G Health launched a large-scale collective awareness effort on Peripheral Neuropathy which was recognized among India's top diabetes campaigns by Obesity International.*

The quarter also saw recognition of our Brand and Citizenship efforts through the prestigious awards – (1) CIMS Annual Wellness and Nutrition Awards 'Trusted Brand of the Year' (Polybion), (2) CIMS Annual Wellness and Nutrition Awards 'Health and Wellness Product of the Year' (Neurobion), (3) India Health & Wellness Awards 'Gold' for Health Awareness Campaign of the year (Neurobion 'Feel Life' and Livogen 'LetHerBreakFree') and (4) India Health & Wellness Awards 'Silver' (SEHAT Public Health Initiative). This has further encouraged us in our commitment to serve Indian consumers and empower them to live healthier and more vibrant lives,” he added.

About Procter & Gamble Health Limited: Procter & Gamble Health Limited is one of India's largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble: P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. P&G operates in approximately 70 countries worldwide.

CONTACTS

Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | mehra.r@pg.com
- Paromita Kundu | kundu.p.1@pg.com

Investor Relations Contact:

- Flavia Machado | machado.f.1@pg.com

Independent Auditor's Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. (as amended)

To the Board of Directors

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited ("the Company") for the quarter ended December 31, 2022 and for the period from July 01, 2022 to December 31, 2022 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as "the said Indian Accounting Standard") and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



HARIBHAKTI & CO. LLP

Chartered Accountants

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048


Sumant Sakhardande

Partner

Membership No.: 034828

UDIN: 23034828 BGNUCK5847

Place: Mumbai

Date: February 05, 2022

